Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

25.05 +0.81 (+3.34%)
Official Closing Price Updated: 7:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
News headline image
Oil Shock Sends Nasdaq, S&P 500 Futures Lower: Why USO, INDO, HIMS, NVDA Are On Traders' Radar Today ↗
Data from Stocktwits showed that retail sentiment on SPY and QQQ remains ‘bearish.’ 
Via Stocktwits
Topics ETFs Economy Government
News headline image
HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗
Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗
According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare. 
Via Stocktwits
Topics Initial Public Offering Intellectual Property Lawsuit
Hims & Hers Health Inc (NYSE:HIMS) Stock Falls on Weak Q1 2026 Revenue Guidance Despite Q4 Earnings Beat ↗
Via Chartmill
News headline image
Tariffs News & Market Chaos ↗
President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown ↗
The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories. 
Via Stocktwits
Topics Earnings Lawsuit
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit
News headline image
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗
The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro. 
Via Stocktwits
Topics Lawsuit
News headline image
Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances ↗
The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale. 
Via Stocktwits
Topics Earnings Supply Chain
News headline image
What's Behind The Jump In Hims & Hers Health Stock? ↗
Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a... 
Via Benzinga
News headline image
Unexpected Stock Picks and Looking to the Future ↗
Why does the shortest month of the year sometimes feel like the longest? 
Via The Motley Fool
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
The stock is down big of late, but the business is by no means doomed. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
MarketBeat Week in Review – 02/23 - 02/27 ↗
Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets... 
Via MarketBeat
News headline image
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key... 
Via StockStory
Topics Economy Government Stocks
News headline image
Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? ↗
The company is looking toward international markets to boost its growth. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising. 
Via The Motley Fool
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think. 
Via The Motley Fool
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report ↗
HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4... 
Via Finterra
Topics Earnings Economy Initial Public Offering
News headline image
Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
HIMS Stock Slumps Nearly 10% After-Hours: How CEO Dudum Plans To Offset GLP-1 Risk ↗
The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. 
Via Stocktwits
Topics Earnings
News headline image
Hims & Hers (HIMS) Earnings Call Transcript ↗
Hims & Hers (HIMS) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million ↗
Hims & Hers Health Inc (NYSE:HIMS) reports financial results for the fourth quarter after the market close on Monday. 
Via Benzinga
News headline image
Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue... 
Via StockStory
News headline image
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
From Hims & Hers
Via Business Wire
News headline image
High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026
As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.